|
Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC). |
|
|
Research Funding - ArQule (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst) |
|
|
Honoraria - Boehringer Ingelheim; Eisai; GlaxoSmithKline; Novartis; Pfizer; Roche/Genentech; Sanofi |
Consulting or Advisory Role - Astellas Pharma; Boehringer Ingelheim; Eisai; GlaxoSmithKline; Novartis; Pfizer; Roche/Genentech |
Research Funding - Amgen; AstraZeneca; Boehringer Ingelheim; Celgene; Eisai; GlaxoSmithKline; Lilly; Novartis; Pfizer; Roche/Genentech; Sanofi |
|
|
No Relationships to Disclose |
|
|
Employment - Lakeside Hospice |
Stock and Other Ownership Interests - Alexion Pharmaceuticals; Enanta |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Novartis; Roche Pharma AG |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Leadership - Aurora Oncology |
Stock and Other Ownership Interests - Aurora Oncology |
Honoraria - BN ImmunoTherapeutics; GTx |
Consulting or Advisory Role - GTX |
Research Funding - Amgen; Aragon Pharmaceuticals; Bavarian Nordic; Bristol-Myers Squibb; Cougar Biotechnology; Dendreon; Exelixis; GlaxoSmithKline; GlaxoSmithKline; GTx; Janssen Oncology; Medivation; Novartis; Pfizer; Roche/Genentech; Sanofi |
Patents, Royalties, Other Intellectual Property - The University of Colorado has filed 2 patents in which I am an inventor. These are related to bladder cancer treatment of early stage disease. |
Travel, Accommodations, Expenses - Bavarian Nordic; GTx |
Other Relationship - Aurora Oncology |
|
|
Stock and Other Ownership Interests - Oncology Metrics |
Consulting or Advisory Role - International Oncology Network; via oncology |
Speakers' Bureau - Biodesix; Celgene |
Research Funding - Bristol-Myers Squibb; Celgene; Genentech/Roche; Gilead Sciences; Pfizer |
Travel, Accommodations, Expenses - RainTree Oncology Services |
|
|
Consulting or Advisory Role - Novartis |
Research Funding - Abbvie; Amgen; AstraZeneca; Genentech; Lilly; Novartis |
|
|
Consulting or Advisory Role - Sanofi |
|
|
Honoraria - Eisai; Janssen; Lilly; Novartis; Sanofi |
Consulting or Advisory Role - Boehringer Ingelheim; Genomic Health; Roche Pharma AG |
Travel, Accommodations, Expenses - Roche Pharma AG |
|
|
Honoraria - GlaxoSmithKline; Pfizer |
Consulting or Advisory Role - GlaxoSmithKline; Roche Pharma AG; Scancell Ltd. |
Speakers' Bureau - GlaxoSmithKline; Pfizer |
Research Funding - Scancell Ltd. |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; GlaxoSmithKline; Merck; Roche Pharma AG |
|
|
|
Consulting or Advisory Role - Novartis |
Travel, Accommodations, Expenses - Novartis |
|
|
|
|
|
|
Stock and Other Ownership Interests - Novartis |
Travel, Accommodations, Expenses - Novartis |
|
|
|
Consulting or Advisory Role - Novartis |
Speakers' Bureau - Novartis |
Research Funding - Novartis |
|
|
|
Stock and Other Ownership Interests - Bristol-Myers Squibb; Novartis; Pfizer |
|
|
Consulting or Advisory Role - Pfizer |
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; GlaxoSmithKline |